Implicit provider bias in cancer clinical trial enrollment: A scoping review
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The lack of racial and ethnic representation in cancer clinical trials further exacerbates existing health disparities and has been linked to inequitable and unequal distribution of resources, social determinants of health, racism, and most recently, provider implicit bias. The purpose of this scoping review is to describe the evidence of implicit bias as it relates to cancer clinical trial enrollment.
Methods
Systematic methods were followed to search online databases for publications that assessed provider bias and cancer clinical trial offers through August 1, 2023. Variables of interest included how implicit bias was defined or measured, what type of bias was examined, and if provider implicit bias was identified or described in the cancer clinical trial enrollment process.
Results
We identified 10 publications that met the inclusion criteria. Nine of ten studies were conducted in the United States, and all studies utilized observational or qualitative study design. Most assessed the provider perspective, and one study used a validated measure to identify implicit bias. Some studies identified evidence of implicit provider bias in clinical trial discussions and offers; however, it was observed in situations where system constraints, such as lack of resources or time were present that may be common in oncological settings.
Conclusions
Multilevel support and dedication to improving racial, ethnic, and other patient-level representativeness are required to mitigate the influence of implicit bias in resource-poor and stressful clinical settings to ensure equitable access to and enrollment in clinical trials for all patients with cancer.
Registration
The protocol for this scoping review was registered to Open Science Framework (1), https://osf.io/a6kbt/?view_only=0a857280364a49b9b3f8363b91b00994 .
